Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Systemic treatment for advanced non-small cell lung cancer (NSCLC) has been significantly advanced by targeted therapies.
• Approved therapies target key molecular drivers such as epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), c-Ros oncogene 1 (ROS1), and V-raf murine sarcoma viral oncogene homolog B (BRAF).
• However, novel molecular targets are continuously emerging, necessitating an updated understanding of their clinical relevance.

Purpose of the Study:

• To review emerging molecular alterations with clinical impact in NSCLC.
• To summarize the current status of targeted agents under investigation for these novel targets.
• To highlight the potential for increased patient benefit through tailored therapeutic approaches.

Main Methods:

• Literature review of current research on molecular alterations in NSCLC.
• Analysis of emerging actionable oncogenic drivers and their targeted agents.
• Synthesis of information on genetic alterations including MET, RET, NTRK, KRAS, PIK3CA, and HER2.

Main Results:

• Identified several key molecular alterations in NSCLC: MET, RET, NTRK, KRAS, PIK3CA, and HER2.
• Detailed the status of targeted agents currently under investigation for these alterations.
• Emphasized the growing body of knowledge on novel drivers and therapies.

Conclusions:

• The identification of new molecular targets and targeted agents is expanding personalized treatment options for NSCLC patients.
• Continuous research into emerging oncogenic drivers is crucial for improving therapeutic strategies.
• Tailored therapeutic approaches based on molecular profiling are expected to benefit a larger proportion of NSCLC patients.